Patients who develop triple-negative breast cancer (TNBC), i.e., those breast cancers that lack amplification of the ERBB2 gene as well as expression of both the oestrogen and progesterone receptors, tend to have a relatively poor prognosis and represent a significant area of unmet clinical need, where novel therapeutic approaches are acutely needed (recently reviewed in ref. [1]). This evidence concerns the gene ERBB2 and breast carcinoma.